What if one of the biggest breakthroughs in addiction treatment has been hiding in plain sight, hiding inside the same pen that’s helped millions shed pounds?
That’s the provocative question raised by new research out of Washington University School of Medicine in St. Louis. Researchers analyzed health records from over 600,000 U.S. veterans with type 2 diabetes and found something that ought to make the medical world sit up and pay attention.
The Numbers Are Hard to Ignore
Here’s the deal: veterans who were taking GLP-1 medications like semaglutide (Ozempic, Wegovy), liraglutide, or dulaglutide were significantly less likely to develop a substance use disorder compared to those on other diabetes medications. We’re talking a 14% reduction in overall risk, but the numbers get more interesting when you break them down by substance.
Alcohol use disorders dropped by 18%. Cannabis by 14%. Cocaine by 20%. Nicotine by 20%. And opioids, the deadliest of the bunch, by 25%.
That’s not a fluke somewhere in the data. That’s a consistent pattern across every major category of addiction researchers examined.
But here’s what really caught my attention. The study didn’t just look at people who hadn’t developed addiction yet. It also tracked more than 81,000 veterans who already had a diagnosed substance use disorder. And the results there were honestly striking: a 30% reduction in emergency department visits, a 25% drop in hospitalizations, a 40% reduction in overdoses, and a 50% reduction in drug-related deaths.
Let those numbers sink in for a second. We’re talking about the most severe outcomes addiction can produce, and GLP-1 users were dramatically less likely to experience them.
It’s Not Treating a Specific Substance. It’s Treating Cravings
What makes this different from existing treatments? Right now, addiction medications tend to be narrow. Naltrexone helps with alcohol and opioids. Nicotine patches help with smoking. There’s nothing that works across the board.
But this research suggests GLP-1 drugs might be doing something fundamentally different. Rather than targeting a specific substance, they might be targeting the underlying craving itself. Senior author Dr. Ziyad Al-Aly put it this way: these medications appear to be acting against the craving that pulls people toward whatever they’re addicted to.
That idea lines up with what we’ve heard from patients for years now. People on GLP-1s for weight loss often describe a quieting of “food noise,” that relentless preoccupation with food. The researchers are now suggesting these drugs might quiet something similar for addictive substances what Al-Aly calls “drug noise.”
Some context: GLP-1 receptors exist in brain regions involved in reward processing. So there’s a plausible biological mechanism here, not just a statistical fluke. This isn’t just correlation.
Let’s Not Get Ahead of Ourselves
Now, I want to be careful here because the researchers themselves would want me to be. This wasn’t a randomized clinical trial. It was an observational study using electronic health records. That means we’re seeing associations, not causation. The veterans weren’t deliberately assigned to take GLP-1s or not take them. Researchers accounted for other factors, but there’s always the possibility something else is driving these results.
The researchers are correctly calling for proper clinical trials to confirm what theyFound. We need rigorously designed studies that can actually measure whether GLP-1s cause these reductions in addiction outcomes, not just whether they correlate with them.
That said, the scale of this data is remarkable. We’re not talking about a few hundred people. We’re talking over half a million. And the effects were consistent across substances and across different outcome measures. That’s the kind of signal that makes you take notice, even if it isn’t definitive proof.
Also worth noting: this work was funded by the U.S. Department of Veterans Affairs, and the researchers explicitly stated the funders had no role in the study design or publication decisions. The study also acknowledges it doesn’t represent the views of the VA or the U.S. government, which is standard language but worth mentioning for transparency.
Why This Matters Beyond the Headlines
If these findings hold up in future research, the implications could be huge. Millions of Americans already take GLP-1 medications for diabetes and obesity. If these drugs also turn out to be effective for addiction, we might have a treatment that addresses multiple conditions at once. For someone struggling with both obesity and a substance use disorder, that could be genuinely transformative.
Here’s what really gets me about this: some of the most dangerous addictive substances, like methamphetamine, have no approved medication treatments at all. If GLP-1s work by targeting craving rather than a specific drug’s effects, they could theoretically fill that gap in ways no current medication can.
This is one of those stories where the initial findings are exciting, but the real work is just beginning. We need clinical trials, we need replication, we need to understand the mechanisms better. But for anyone who has watched addiction devastate families and communities, this research represents something rare: a genuinely new avenue worth pursuing.
The roar of addiction is relentless for millions of people. If we can find a way to quiet it, we owe it to everyone suffering to investigate thoroughly.
This reporting is based on research from WashU Medicine. The findings are observational and require further clinical validation.
